Alto Neuroscience Q2 net loss $17.7M; ALTO-207 acquisition expands TRD pipeline; data readouts ahead

Alto Neuroscience, Inc.

2025-Q2 EPS reported -$1.21 vs consensus -$0.63 ▼ miss (-93.5%)

Net loss $17.7M in Q2 2025 vs $16.0M in Q2 2024; cash $148.1M expected to fund operations into 2028.
Acquired ALTO-207 (pramipexole/ondansetron) from Chase; Phase 2b in TRD planned by mid-2026.
ALTO-101 Phase 2 POC topline data for CIAS expected 2H 2025; ALTO-300 Phase 2b MDD data mid-2026.
ALTO-100 Phase 2b bipolar depression data expected 2H 2026; ALTO-203 showed positive pharmacodynamic results.
Appointed Raymond Sanchez, M.D., to Board; class structure reconstituted, committee assignments updated.

item 2.02item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.